HDAC9 and Cirrhosis: The risk signature may be a useful tool to set up more individualized follow-up interval schedules and HDAC inhibitors, such as trichostatin A, vorinostat, and valproic acid, may be exploited to be a potential chemopreventive treatment for the prevention of HCC development for cirrhosis patients.